New data involves nonviral, targeted payload delivery to the liver using ultrasound mediated delivery (UMD), resulting in up ...

Clinical data from investigator-initiated trials in 20 patients with multiple autoimmune diseases show allogeneic CAR-T QT-019B was generally well tolerated and demonstrated encouraging efficacy –– QT ...

Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed or refractory follicular lymphoma based on first data from single-arm cohort of Phase III CELESTIMO study –– Data ...

Bristol Myers Squibb (NYSE: BMY) reinforces its hematology leadership through new research across multiple therapies for patients with lymphoma at the 67th American Society of Hematology (ASH) Annual ...

Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT), highlighting its potential as a treatment option ...

AbCellera (Nasdaq: ABCL) today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference ...

Preclinical data findings illustrate power of Cellarity’s discovery platform, which leverages transcriptomics and AI to discover previously unseen biological pathways to create novel cell ...

Jaguar CEO Lisa Conte presenting December 10 from 3:25pm - 3:35pm Eastern at the Emerging Growth Conference to provide updates on near-term catalysts; Click here to registerInitial results of ongoing ...

Technion’s highest honor recognizes Mirkin for pioneering discoveries in nanoscience, including the Spherical Nucleic Acid (SNA) technology that forms the foundation of Flashpoint’s structural ...

HACKENSACK, NJ / ACCESS Newswire / December 8, 2025 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for the ...

The "Chiplet Market - Global Forecast to 2030" has been added to ResearchAndMarkets.com's offering.The chiplet market is set for significant growth, projected to reach USD 157.23 billion by 2030 from ...

Abcuro, Inc., a late-stage clinical biotechnology company developing potentially first-in-class immunotherapies designed to ...